Isomorphic Labs, the AI drug research company led by DeepMind co-founder Demis Hassabis, has closed a $2.1 billion Series B round led by Thrive Capital. The funding will go toward expanding its in-house platform IsoDDE and advancing drug candidates toward clinical trials. The article Alphabet's Isomorphic Labs raises $2.1 billion to scale AI drug discovery toward clinical trials appeared first on The Decoder.